![](https://investorshub.advfn.com/uicon/280555.png?cb=1594066301)
Monday, September 11, 2023 8:19:20 AM
EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)-- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.
Amniotic Tissue Allograft provides a protective environment or covering for repair of the cornea and conjunctiva, helping ocular surface to return to a healthier state. NovaBay intends to commercialize the prescription-only product as Avenova Allograft to leverage its Avenova eyecare brand and encourage use with other Avenova products. Medically necessary procedures with the Avenova Allograft will be reimbursed through Medicare.
Placentally derived human amniotic membrane is a potent source of pro-healing growth factors and anti-inflammatory cytokines. Amniotic allografts have successfully been used in regenerative medicine for over a century and dehydrated human amniotic membrane continues to be widely used as an ophthalmic covering. Avenova Allograft is the only optic allograft manufactured using BioStem Technologies’ patented six-step BioREtain® process that preserves the natural integrity of the placental tissue. This new NovaBay-branded product will compete in the global ophthalmology amniotic membrane market estimated at $403.6 million in 2022, and is expected to grow at 9.8% per year between 2023-2030.
“Avenova Allograft is a differentiated, high-quality product making it an ideal extension of our eyecare franchise,” said Justin Hall, CEO and General Counsel of NovaBay. “We look forward to launching Avenova Allograft in the coming weeks and making this valuable solution available for the eyecare professionals who specialize in treating dry eye.”
“Avenova Allograft is an ultra-thin, ultra-light structural tissue allograft composed of the amnion layer of the placental membrane. Our proprietary six-step BioREtain manufacturing process preserves the natural components of the tissue critical to the wound healing process and creates a product that is high-quality, versatile, and is applicable to a wide variety of topical ophthalmic covering applications. It is easy to use, and has no harsh chemicals or cryopreservants,” said Jason Matuszewski, CEO of BioStem Technologies. “Our company has an unwavering commitment to innovation, developing superior processes and delivering high-quality products. We manufacture products that change lives!”
About NovaBay Pharmaceuticals, Inc.:
Recent NBY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 12:47:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 11:30:13 AM
- NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American • Business Wire • 06/07/2024 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:50:08 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/31/2024 08:43:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:31:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:29:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:27:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:24:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:17:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 09:27:32 PM
- NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates • Business Wire • 05/29/2024 09:22:00 PM
- NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms • Business Wire • 05/13/2024 12:30:00 PM
- NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results • Business Wire • 05/09/2024 08:05:00 PM
- NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon • Business Wire • 05/07/2024 12:00:00 PM
- NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024 • Business Wire • 05/03/2024 10:50:00 AM
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales • Business Wire • 04/22/2024 10:57:00 AM
- NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity • Business Wire • 04/19/2024 10:00:00 PM
- NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses • Business Wire • 04/17/2024 10:59:00 AM
- NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results • Business Wire • 03/26/2024 08:05:00 PM
- NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024 • Business Wire • 03/25/2024 10:38:00 PM
- NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023 • Business Wire • 03/14/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:52:33 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 04:52:28 PM
- NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales • Business Wire • 01/30/2024 02:00:00 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM